Abstract 458P
Background
Venous Thromboembolism (VTE) is a common cardiovascular disease affecting cancer patient with related poor prognosis and short survival. Different scoring systems and certain genetic polymorphisms were used to predict patient's risk for VTE. This study aimed to investigate the association between TSPAN15 (rs78707713) and SLC44A2 (rs2288904) genetic polymorphisms and VTE in cancer patients in correlation with PROTECHT scoring system and survival.
Methods
This case control study was carried out on 100 cancer patients, group I included 50 consecutive cancer patients with VTE, and group II included 50 selected cancer patients without VTE with age and cancer diagnosis matched to group I as a control. Full history taking and clinical examination and all clinical data were recorded. Laboratory investigations including CBC, coagulation profile and analysis of TSPAN15 (rs78707713) and SLC44A2 (rs2288904) SNPs by PCR were assessed. Radiological imaging of VTE by duplex ultrasound, CT pulmonary angiography were done according to the clinical scenario. PROTECHT score and survival analysis were calculated.
Results
Cancer patients with VTE had high tumor grade, increased incidence of metastasis with shorter progression free survival (PFS) compared with cancer patients without VTE. Partial immobilization and hospitalization were significantly associated with the occurrence of VTE in cancer patients. Regarding cancer treatment, the use of gemcitabine-based chemotherapy was associated with an increased risk for VTE. The most frequent SLC44A2 (rs2288904) genotype was GG followed by AG in cancer patients with VTE. Whereas GG and AG genotypes were equally distributed in cancer patients without VTE, The GG genotype had high risk PROTECHT score compared with AA and AG genotypes. The commonest TSPAN15 (rs78707713) genotypes were TC and CC in cancer patients with VTE versus TC and TT in cancer patients without VTE. The CC genotype had high PROTECHT score points compared with TC and TT genotypes. Furthermore, TC and CC cancer patients with VTE had significantly high tumor grade.
Conclusions
Screening of SLC44A2 (rs2288904) and TSPAN15 (rs78707713) genetic variants may enhance the ability to predict VTE risk in cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Menoufeya University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
174P - Unlocking the potential of blood-based biomarkers in pancreatic cancer for early detection and therapeutic screening
Presenter: Belinda Lee
Session: Poster Display
Resources:
Abstract
175P - Genomic evolution of peritoneal metastasis in gastric adenocarcinoma
Presenter: Lan Tu
Session: Poster Display
Resources:
Abstract
176P - Identification of novel diagnostic markers for pancreatic neuroendocrine tumors by proteomics with patient blood
Presenter: HEE SEON Kim
Session: Poster Display
Resources:
Abstract
177P - Burden of stomach cancer attributable to smoking in South Asia from 1990-2019, its projection of deaths to 2040: A benchmarking and comparative analysis
Presenter: Pranay Vaghela
Session: Poster Display
Resources:
Abstract
178P - Survival benefit of splenic hilar lymph nodes (no.10) dissection in B4 type gastric carcinoma: An IPTW propensity score analysis of large multi-institutional data
Presenter: Oh Jeong
Session: Poster Display
Resources:
Abstract
179P - The impact of pre-operative nutritional/rehabilitative assessments and support on postoperative outcomes in very elderly gastric cancer patients
Presenter: Yuki Ushimaru
Session: Poster Display
Resources:
Abstract
180P - Appraisal of surgical outcomes and oncological efficiency of intraoperative adverse events in robotic radical gastrectomy for gastric cancer
Presenter: shangguan Zhixin
Session: Poster Display
Resources:
Abstract
181P - TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study
Presenter: Zhen Huang
Session: Poster Display
Resources:
Abstract
182P - Cytoreductive surgery and chemotherapy in metastatic gastric adenocarcinoma: A population-based study
Presenter: Dana Al Zamer
Session: Poster Display
Resources:
Abstract